Chips Stocks Up, Inovio & Alcon Down: Upside Downside Movers in the A.M.
Upside
– $FOSL +23% (Q3 beat, gross margin surged and the FY sales and profit outlook was raised)
– $SATL +21% (record Q3 revenue, positive adjusted EBITDA and a post-quarter deal to sell three in-orbit satellites for about $37M)
– $RSKD +20% (Q3 revenue growth accelerated to 41% and revenue and adjusted EBITDA guidance was raised for a third time)
– $GEVO +18% (record Q3 results and higher 2026 EBITDA outlook, helped by carbon-credit sales)
– $CRWV +15% (Q3 revenue beat, the FY outlook was raised and backlog climbed to $132.5B)
– $NBIS +13%, $IREN +7.7%, $DELL +8.1%, $SMCI +5.8%, $VRT +6.2%, $ORCL +5.2% (AI-infrastructure names rise as CoreWeave’s beat-and-raise and customer-prepayment outlook ease demand and funding fears)
– $LITE +9.8%, $COHR +10.1%, $CRDO +8.1%, $AXTI +9.7%, $CIEN +7.9%, $AAOI +7.2% (AI-networking and optical suppliers rally on the stronger infrastructure-demand read-through)
– $STX +9.4%, $SNDK +8.8%, $WDC +8.7%, $MU +7.5% (AI storage and memory names rise on stronger infrastructure-demand expectations)
– $MRVL +9.3%, $TER +7.2%, $ALAB +8.2%, $ARM +6.6%, $INTC +6.5%, $AMD +5.6% (chip complex rallies as CoreWeave’s outlook reassures investors on AI compute demand)
– $NVDA +3.8%, $AVGO +4.5% (megacap chip names rebound as AI-infrastructure sentiment improves)
Downside
– $INVZ -17% (Q3 revenue missed badly and FY sales guidance came in far below expectations)
– $LWLG -16% (volume-production target slipped to 2028 as foundry and qualification delays extended timelines)
– $BV -13% (Q4 missed and FY2027 revenue guidance fell short)
– $GPRO -10% (delayed its Q3 filing and warned lender defaults could jeopardize the planned merger)
– $STIM -10% ($30M underwritten offering priced at $1.60 a share)
– $INO -9.7% (Q3 loss missed expectations despite the recent FDA approval, while fresh financing added stock supply)
– $VELO -8.1% (Q3 loss widened, the gross-margin target was withdrawn and the positive-EBITDA timeline moved to 2028)
– $ALC -4.2% (sales missed as implantables weakened, while market-growth and EPS-growth outlooks were narrowed)
